Lannett To Acquire Two Generic Pharmaceutical Products

Loading...
Loading...
Lannett Company, Inc.
LCI
today announced that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The company did not disclose the name of the seller nor the financial terms of the transaction. Lannett expects to launch Estradiol Tablets within the next several months and Selegiline Hydrochloride Capsules sometime thereafter. According to IMS, for the full year 2013 total sales of Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg at Average Wholesale Price (AWP) were approximately $31.0 million and $8.5 million, respectively. The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories (now a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.); Selegiline Hydrochloride Capsules 5 mg is the generic equivalent of Somerset Pharmaceuticals, Inc.'s Eldepryl®. “We are pleased to add Estradiol Tablets and Selegiline Hydrochloride Capsules to our offering,” said Arthur Bedrosian, president and chief executive officer of Lannett. “The acquisition of these two important
Posted In: NewsLegalPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...